Despite trade speculation, Madison Bumgarner arrived at Scottsdale Stadium on Tuesday as Giants pitchers and catchers reported for Spring Training. He's still on track to be the club's starter on Opening Day, though his future in San Francisco remains murky as he prepares to enter his final season before free agency.

The Giants added another arm into their bullpen mix Wednesday, acquiring right-hander Trevor Gott from the Nationals for cash considerations.

Less than two hours after meeting Madison Bumgarner, top Giants prospect Joey Bart found himself catching one of Bumgarner's bullpen sessions after the veteran left-hander approached him and said, "Let's go on No. 1."

The 30 prospects below all are getting very long looks this spring with an eye toward breaking camp with the parent club. Even if they start the year in the Minors, they all should get the chance to contribute at some point in the very near future.

The Giants have expressed a desire to add multiple veteran outfielders throughout the offseason, and they made their first notable acquisition earlier this week after signing Gerardo Parra to a Minor League contract.

The road back from Tommy John surgery is often long and tedious, but Giants right-hander Johnny Cueto has a notable milestone approaching.

Steven Duggar and Ryder Jones continue to take steps forward in their rehab, as they were both cleared to take batting practice on the field Friday for the first time since their September surgeries.

Seeking to bring another versatile infielder into the fold, the Giants on Friday agreed to terms with Yangervis Solarte on a Minor League contract with an invitation to Major League Spring Training.

Shortly after reporting to Giants camp this week, Pablo Sandoval met with manager Bruce Bochy and reiterated his desire to help the club in whatever way he can.

On this opening week of Spring Training, all 30 Major League teams have one thing in common: optimism. Here's an optimism cheat sheet for each of them.

Pablo Sandoval said he recruited his friends Gerardo Parra and Yangervis Solarte to the Giants in the offseason.

Who do the Giants have in the pipeline? Get scouting reports, video, stats, projected ETAs and more for San Francisco's Top 30 Prospects on MLB Pipeline's Prospect Watch.

Heading into his 13th year in the Majors, Cameron Maybin brings a fresh approach at the plate and a revamped swing as he looks to carve out playing time in the Giants' outfield.

Bruce Bochy isn't sure what his next step will be after he retires from managing the Giants at the end of the season, but it's safe to assume that a trip to Cooperstown is in his near future.

The next five weeks will see lots of shuffling on Major League rosters. Here are the most intriguing positional battles on each of the 30 MLB clubs.

Bruce Bochy, who guided the Giants to three World Series championships in 2010, '12 and '14, announced Monday that he will retire at the end of the 2019 season, capping a celebrated 25-year managerial career in the Majors.

Bruce Bochy announced on Monday that his 25th season as a manager -- his 13th in an absurdly successful run with the Giants -- would be his last. In making the announcement, Bochy is going to give all of us the opportunity to say thanks during a 2019 season that will be something of a victory lap whether he likes it or not.

Buster Posey has known only one manager since making his debut with the Giants a decade ago. While it's hard for him to envision playing for someone other than Bruce Bochy, he wasn't surprised to hear about his longtime manager's plans to retire after the 2019 season.

Giants president of baseball operations Farhan Zaidi knows he will eventually have to start compiling a list of potential candidates to succeed Bruce Bochy as manager, but the upcoming search isn't currently at the forefront of his mind.

The life cycle of malaria parasites in both their mammalian host and mosquito vector consists of multiple developmental stages that ensure proper replication and progeny survival. The transition between these stages is fueled by nutrients scavenged from the host and fed into specialized metabolic pathways of the parasite. One such pathway is used by Plasmodium falciparum, which causes the most severe form of human malaria, to synthesize its major phospholipids, phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. Much is known about the enzymes involved in the synthesis of these phospholipids, and recent advances in genetic engineering, single-cell RNA-Seq analyses, and drug screening have provided new perspectives on the importance of some of these enzymes in parasite development and sexual differentiation and have identified targets for the development of new antimalarial drugs. This Minireview focuses on two phospholipid biosynthesis enzymes of P. falciparum that catalyze phosphoethanolamine transmethylation (PfPMT) and phosphatidylserine decarboxylation (PfPSD) during the blood stages of the parasite. We also discuss our current understanding of the biochemical, structural, and biological functions of these enzymes and highlight efforts to use them as antimalarial drug targets.

Many chemicals and cellular processes cause oxidative stress that can damage lipids, proteins, or DNA (1). To quickly sense and respond to this ubiquitous threat, organisms have evolved enzymes that neutralize harmful oxidants such as reactive oxygen species and electrophilic compounds (including xenobiotics and their breakdown products) in cells.These antioxidant enzymes include GSH S-transferase (GST),2 NADPH:quinone oxidoreductase 1, thioredoxin, hemeoxygenase-1, and others (2, 3). Many of these proteins are commonly expressed in cells exposed to oxidative stress.The antioxidant response element (ARE) is a major regulatory component of this cellular stress response. The ARE is a conserved, 11-nucleotide-long DNA motif present in the 5'-flanking regions of many genes encoding antioxidant proteins. The laboratory of Cecil Pickett (Fig. 1) at the Merck Frosst Centre for Therapeutic Research in Quebec discovered ARE, a finding reported in the early 1990s in two JBC papers recognized as Classics here (4, 5).jbc;295/12/3929/F1F1F1Figure 1.Cecil Pickett (pictured) and colleagues first described the ARE motif, present in the 5' regions of many genes whose expression is up-regulated by oxidative stress and xenobiotics. Photo courtesy of Cecil Pickett.ARE's discovery was spurred in large part by Pickett's career choice. After completing a PhD in biology and a 2-year postdoc at UCLA in the mid-1970s, he began to work in the pharmaceutical industry.Recruited to Merck in 1978 by its then head of research and development (and later CEO), Roy Vagelos, “I became interested in how drug-metabolizing enzymes were induced by various xenobiotics,” Pickett says.According to Pickett, Vagelos encouraged researchers at the company...

2 May 2019 , Volume 95, Number 3